#remlifanserin

1 story

#acadia #biotech #clinical endpoint #clinical trial #pipeline expansion #stock price

Acadia Pharmaceuticals Stock Plummets After Clinical Failure
Acadia Pharmaceuticals shares drop 8.6% after remlifanserin trial misses primary endpoint
Alphastreet - Earnings Decoded. Market Intelligence Delivered · 1m